具有新型作用机制的抗结核药物

Anti-tuberculosis Drugs with Novel Mechanism of Action

结核病(Tuberculosis)是世界范围里的主要疾病之一,近年来,每年约有180万人死于结核病,结核病已经成为全球性的公众健康问题。近年来药物耐受以及伴有HIV感染的结核病发病率急剧增加,迫切需要深入了解目前抗结核药物的作用机制及耐药机制,以指导开发对持留菌和耐药菌更加有效的新型药物。近年来,一批具有全新作用机制的抗结核候选药物相继进入了临床研究,并且这些药物对耐药株表现出有效的抑制活性。文章对几类新型抗结核药物的化学结构、作用机制、构效关系、抗结核活性以及临床应用进行了综述。

Tuberculosis is one of major health problems worldwide.Approximately 1.8 million people died from Tuberculosis each year which has become a global public health issue.Recently the emergence of drug resistant strains and HIV co-infection has resulted in a high incidence.As a result,there is an urgent need for us to understand the resistance mechanism and discover new anti-tuberculosis drugs.A number of new potential anti-tuberculosis drug candidates with novel modes of action have entered clinical trials in recent years.These agents are most likely to be effective against resistant strains.The paper summarized structure-activity relationships,in vitro and in vivo activity,pharmacokinetics,mechanism of action and combination regimens about several novel anti-tuberculosis drugs.